Showing results (81-90 of 241) with videos related to
Sort By:
Pageof 25
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.The Oncologist|October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unitSiqing Fu, Lacey McQuinn, Aung Naing, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.Oncoscience|January 17, 2015
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancerGerald S Falchook, Aung Naing, Jennifer J Wheler, et al.Oncotarget|July 9, 2014
Characteristics and survival of patients with advanced cancer and p53 mutationsRabih Said, Yang Ye, David S Hong, et al.Cancer|June 8, 2012
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignanciesRazelle Kurzrock, Sanjay Goel, Jennifer Wheler, et al.Oncotarget|May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapyRabin Said, David S Hong, Carla L Warneke, et al.Expert Opinion on Therapeutic Targets|May 26, 2015
Targeting drug transport mechanisms for improving platinum-based cancer chemotherapyHelen H W Chen, Wen-Chung Chen, Zhang-Dong Liang, et al.Pageof 25